Tesamorelin Growth Hormone-releasing Factor Reduces Visceral Fat in Patients

[ElZorro]

These findings led the researchers conclude that "Tesamorelin significantly reduces visceral adipose tissue in different sub-populations of HIV-infected patients with abdominal lipohypertrophy, including women, patients with hepatitis, patients with detectable viral loads, and non-Caucasians," and did so "without any clinically meaningful differences in long-term safety."

"Tesamorelin significantly decreases VAT in HIV positive patients with excess abdominal fat," the researchers concluded.

"Assessment of VAT using CT scan is a research technique," they noted, "but the degree to which VAT is reduced in response to tesamorelin is apparent to patients based on significant reductions in waist circumference and improvements in body image that are highly correlated with reductions in VAT."

Tesamorelin is currently under review by the U.S. Food and Drug Administration. An FDA advisory committee unanimously recommended approval in June, but the expected late July decision date came and went with no action. The agency has now indicated that it expects to make a ruling later this fall.


http://www.hivandhepatitis.com/2010_conference/icaac/docs/0928_d.html

[Hellraiser]

The problem with this drug is that like Elgrifta and any analog of Human Growth Hormone it has a tendency to cause Diabetes in the people who take it.

[Assurbanipal]

Actually, tesamorelin is Egrifta -- you may find more stories if you search on that name.

[Hellraiser]

Actually, tesamorelin is Egrifta -- you may find more stories if you search on that name.

I actually thought this might be the case as they were being talked about around the same time frame and in the same manner, but wasn't absolutely sure.

[ARMANDO]

is anybody presently taking SEROSTIM?

[Assurbanipal]

November 11, 2010

Egrifta Gets FDA Approval for HIV-Associated Lipodystrophy



Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from the U.S. Food and Drug Administration (FDA). The drug, requiring once-daily injections, was approved to reduce visceral adipose tissue (VAT)— deep belly fat surrounding the liver, stomach and other abdominal organs—in people living with HIV experiencing lipodystrophy, a side effect of antiretroviral (ARV) therapy.

http://www.aidsmeds.com/rssredir/articles/egrifta_tesamorelin_approval_1667_19389.shtml

[netta]

I am wondering if you would have to take tesamorelin for long term. If short term can this reduce the chance of diabeties, and if used short term ,will it reverse itself when stopped I sure am excited about it since I am 5'1 and have a stomach growing below my breast and have no waist. I look 6 mos. pregnant!